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This review summarises not only the latest evidence on pre-
vention, but also the current research on the treatment of
early-stage breast cancer patients. Recent years have seen a
growing body of evidence on the risk of high- and moderate-
penetrance breast cancer susceptibility genes. A large inter-
national consortium has now been able to further refine the
answer to the question of the significance of the so-called
panel genes. Moreover, the data on treatment selection re-
garding endocrine efficacy and the decision for or against
chemotherapy have also been advanced markedly. There is al-
so new data on adjuvant CDK4/6 (cyclin-dependent kinase 4/
6) inhibitors, which are standard in first-line treatment in pa-
tients with metastatic HER2-negative, hormone receptor-pos-
itive (HR+) breast cancer. For other therapies such as immune
checkpoint inhibitors, which have successfully improved the
rate of pathologic complete response (pCR) in neoadjuvant
treatment settings for patients with triple-negative breast
cancer (TNBC), there is a growing understanding of the qual-
ity of life and side effects. This is especially important in situa-
tions where patients could possibly be cured without such a
regimen.
ZUSAMMENFASSUNG
In dieser Übersichtsarbeit werden nicht nur die neuesten Er-
kenntnisse zur Prävention, sondern auch die aktuellen Arbei-
ten zur Behandlung von Mammakarzinompatientinnen im
frühen Krankheitsstadium zusammengefasst. In den letzten
Jahren haben sich die Hinweise über hoch-penetrante und
mittelgradig penetrante Risikogene für ein Mammakarzinom
verdichtet. Nun konnte in einem großen internationalen Kon-
sortium die Antwort auf die Frage nach der Wertigkeit der so-
genannten Panelgene weiterentwickelt werden. Des weiteren
sind auch die Daten zur Therapieselektion in Bezug auf endo-
krine Wirksamkeit und die Entscheidung für oder gegen eine
Chemotherapie deutlich weiterentwickelt worden. Ebenso
gibt es neue Daten zum adjuvanten Einsatz von CDK4/6-(Cy-
clin-dependent-kinase-4/6-)Inhibitoren, die in der 1. Therapie-
linie für Patientinnen mit metastasiertem HER2-negativem,
hormonrezeptorpositiven (HR+) Mammakarzinom zum The-
rapiestandard gehören. Bei anderen Therapien wie den Im-
muncheckpoint-Inhibitoren, welche erfolgreich in der neo-
adjuvanten Therapiesituation bei Patientinnen mit einem tri-
ple-negativen Mammakarzinom (TNBC) die Rate an patholo-
gischen Komplettremissionen (pCR) verbessern konnten,
wächst das Verständnis für Lebensqualität und Nebenwirkun-
gen. Dies ist von besonderer Bedeutung in einer Situation, in
der Patientinnen potenziell auch ohne eine solche Therapie
geheilt werden könnten.Introduction
This review summarises the latest study outcomes in prevention
and treatment of patients with early-stage breast cancer. Devel-
opments in recent years have shown that treatment innovations
enter clinical practice at a rapid pace [1–6]. This paper includes
full publications and presentations at the current major cancer
and breast cancer meetings such as ESMO (European Society for
Medical Oncology) 2020 and SABCS (San Antonio Breast Cancer
Symposium) 2020. During the COVID-19 pandemic, these meet-
ings were largely held in a virtual setting. Due to the pandemic, it
is not just medical communication that has suffered. Far more sig-
nificant is the drop in patient participation in screening and diag-
nostic procedures, the restrictions on planned interventions and
procedures with medical indications, as well as the resulting de-
cline in the patientsʼ quality of life.Stickeler E et al. Update Breast Cancer… Geburtsh Frauenheilk 2021; 81: 526–538 | © 2021. ThPrevention
Panel gene knowledge deepens
All inherited genetic risk factors can explain about 40% of a two-
fold increased familial risk of breast cancer [7–9]. Risk genes are
divided into those with high, moderate and low penetrance. These
largely comprise common polymorphisms for which over 150 ge-
nomic regions have been identified [10–27]. BRCA1/2 accounts
for about 16% and low-penetrance genes for about 18% of this
familial risk [28]. Medium penetrance genes could explain about
4% of the twofold increase in familial risk [28]. Often these genes
were included in so-called gene panels evaluated as part of genet-
ic counselling and testing (e.g., PALB2, ATM, CHEK2, …). This has
been the subject of much discussion in recent years and studies
have been undertaken to quantify the risk of these genes [29,
30]. As is also evident from ▶ Fig. 1, in both papers the lifetime
risk of moderate-penetrance risk genes was lower than for BRCA1
or BRCA2 (except PALB2) [31,32]. In over 60000 female breast527e author(s).
▶ Table 1 The risk genes studied in over 60000 breast cancer
patients and more than 53400 healthy controls.
ABRAXIS1 CHEK21 MSH6 RAD50
AKT1 EPCAM MUTYH RAD51C2
ATM1 FANCC NBN RAD51D2
BABAM2 FANCM NF1 RECQL
BARD12 GEN1 PALB21 RINT1
BRCA11 MEN1 PIK3CA STK11
BRCA21 MLH1 PMS2 TP532
BRIP1 MRE11 PTEN XRCC2
CDH1 MSH2
1 Breast cancer risk correlation with a p-value < 0.0001
2 Breast cancer risk correlation with a p- value < 0.05
bold = confirmed breast cancer risk genes with high or moderate pene-
trance




























▶ Fig. 1 Lifetime risk up to 80 years of age for the eight confirmed risk genes according to [31].
GebFra Science | Reviewcancer patients and more than 53400 healthy controls, 34 puta-
tive risk genes were sequenced and screened for protein truncat-
ing mutations and rare missense mutations [31]. The genes
studied are listed in ▶ Table 1. ATM, BRCA1, BRCA2, CHEK2, and
PALB2 clearly correlated with an increased risk of breast cancer.
BARD1, RAD51C, RAD51D, and TP53 also correlated with breast
cancer risk, but not as markedly as those noted above. ▶ Fig. 1
presents the cumulative lifetime risks according to Dorling et al.
up to the age of 80 years. It becomes clear that in the risk range
45–60% BRCA1, BRCA2 and PALB2 together should be classified as
high-penetrance risk genes, while the other confirmed risk genes
with lifetime risks of 20–30% may be regarded as moderate risk
genes. Ultimately, this paper, with more than 110000 patients,
provides the foundation for risk counselling. Even though no sig-
nificant correlation was found for the remaining genes, this does
not imply that they are not risk genes, but only that in this study
design they did not attain risk ranges comparable to these eight
confirmed genes. The role of these risk genes in the treatment of
breast cancer is unclear. While carriers of the BRCA1/2 mutation
respond better to chemotherapy or PARP (poly-[ADP-ribose]-
polymerase) inhibitors [33–38] in the neoadjuvant setting and
to PARP inhibitors when metastasis is present [39–41], for the
other mutations evidence that patients have a good chance of re-
sponding to olaparib therapy could only be found for PALB2 [42].
Impact of diet and microbiome on breast cancer risk
It has already been established in some epidemiological studies
that body weight impacts on the risk of breast cancer. Interesting-
ly enough, in premenopausal women, a high BMI (body mass in-
dex) does not appear to be associated with increased risk. In post-
menopausal women, on the other hand, a high BMI correlates
with an increased risk of breast cancer [43–45]. Moreover, there
seem to be other metabolic factors affecting the risk of breast528 Stickeler E et al.cancer independently of BMI [43]. With regard to prognosis, it
has also been established that obesity has a negative effect on
the course of the disease and the molecular subtype [46,47] This
suggests a link between metabolism and breast cancer risk with
more complex mechanisms. One study looking into this is the co-
hort study “NutriNet-Santé” [48]. It investigated the possible cor-
relation between a high glycaemic index (a measure of the hyper-
glycaemic effect of food containing carbohydrates) and high gly-
caemic load with an increased risk of breast cancer. In the study,
which was controlled by online questionnaires, more than
171000 respondents were questioned every 6 months about diet
and lifestyle, among other things. Over 81000 women were eval-
uated in quintiles regarding the topic. 927 breast cancer casesUpdate Breast Cancer… Geburtsh Frauenheilk 2021; 81: 526–538 | © 2021. The author(s).
were observed. It was shown that unlike postmenopausal women
in the lowest quintile of glycaemic load those in the highest quin-
tile were at a significantly higher risk of breast cancer with a haz-
ard ratio of 1.64 (95% CI: 1.06–2.55). Similarly, compared with
the bottom quintile the share of diet with moderate and high gly-
caemic index in the top quintile correlated with an increased risk
of breast cancer in pre- and postmenopausal women (HR = 1.48;
95% CI: 1.18–1.86) [48]. This study thus revealed that the compo-
sition of the diet can affect the risk of breast cancer. Since the
analysis included BMI, height, physical activity, and other con-
founders as well, it can also be stated that this risk from diet is in-
dependent of these other parameters.
In the past, the gut microbiome has already been linked to the
efficacy of immunotherapy in cancer patients [49]. The associa-
tion between gut microbiome and breast cancer risk has also been
studied [50] by now based on an existing large case-control study
of over 130000 breast cancer cases and more than 110000 con-
trols [51]. Moreover, studies were included that had investigated
the correlation between genetic variants and the presence of spe-
cific microbiome patterns [52]. The 13 genetic variants correlat-
ing with specific microbiome patterns [52] were then studied by
Mendelian randomisation for their correlation with breast cancer
risk in the large case-control study [51]. In the overall population,
the bacterial genus ruminococcus was identified as a risk factor. In
triple-negative breast cancer (TNBC), bacteria of the genus para-
bacteroides have been identified as protective and unclassified
bacteria of the order bacteroidales as risk factors [50]. However,
as the interaction between health and the microbiome is not yet
fully understood, it is difficult to establish a risk-reducing inter-
ventional strategy based on this data.Neoadjuvant Therapy
Neoadjuvant treatment in patients with hormone
receptor-positive HER2-negative tumours
Although pathologic complete response (pCR) generally predicts
good outcome after neoadjuvant chemotherapy, this effect is
most pronounced in patients with HER2-positivity or TNBC [53–
57]. In patients with HR+/HER2− tumours, the interaction is less
evident, which is why understanding resistance mechanisms in
the neoadjuvant setting is of particular clinical relevance. An im-
portant clinical issue is whether chemotherapy is associated with
a benefit in endocrine resistance or endocrine sensitivity. Ki-67
and multigene tests would seem to be promising biomarkers in
this setting. The response to endocrine treatment resulting in Ki-
67 decline within a few weeks was a significant prognostic marker,
e.g. in the POETIC trial [58].
Absence of Ki-67 response under endocrine therapy
and subsequent neoadjuvant chemotherapy
ALTERNATE is a new trial looking at these mechanisms. In this trial
HER2−/HR+ patients with elevated Ki-67 levels persistently > 10%
after initial neoadjuvant endocrine therapy underwent neoadju-
vant chemotherapy. Data has been reported from this arm re-
garding the neoadjuvant chemotherapy [59]. Of the 1299 pa-
tients enrolled in the trial, 286 patients had a Ki‑67 level > 10%Stickeler E et al. Update Breast Cancer… Geburtsh Frauenheilk 2021; 81: 526–538 | © 2021. Thafter renewed core needle biopsy under neoadjuvant endocrine
therapy. 168 of these 286 patients underwent neoadjuvant che-
motherapy, while the remaining patients were operated on di-
rectly. 14 patients with neoadjuvant treatment did not undergo
surgery. Only 8 patients (4.8%; 95% CI: 2.1–9.2) achieved a pCR,
despite the fact that more than 80% of the tumours tested Ki-67
> 20% [59]. In another trial in which the Ki-67 level was estab-
lished before chemotherapy, the pCR rate in Ki-67 of 20% was a
similar 8% [55]. Whether re-biopsy under endocrine therapy can
provide more information than the initial Ki-67 level should be in-
vestigated further. The results of this trial cannot be applied in
clinical practice when deciding for or against neoadjuvant chemo-
therapy or initial surgery.
Also in the ADAPT study HR+ HER2− patients were selected for
a neoadjuvant chemotherapy based on a multigene test (Onco-
typeDX®) and a Ki-67 assessment after a 3-week endocrine treat-
ment [60]. Eligible for neoadjuvant chemotherapy were patients
with a recurrence score of > 25 or more than 3 positive lymph
nodes and patients with > 10% Ki-67 positive cells in the repeat
core needle biopsy 3 weeks after endocrine treatment [60]. Pa-
tients were randomised into one of two arms: 4 cycles of paclitax-
el 175mg/m2 every 2 weeks followed by 4 cycles of epirubicin/cy-
clophosphamide every 2 weeks versus 8 cycles of Nab-paclitaxel
125mg/m2 weekly followed by 4 cycles of epirubicin/cyclophos-
phamide every 2 weeks. In the paclitaxel arm, the pCR rate was
12.9% and in the Nab-paclitaxel arm 20.8% (p = 0.002) [60]. Thus,
after demonstrating better efficacy of Nab-paclitaxel versus pacli-
taxel in the neoadjuvant treatment of TNBC patients [61], it has
now also been shown in HER2−, HR+ patients that the pCR rate
could be almost doubled [61]. These outcomes confirm the pCR
results of the GeparSepto trial in triple negative patients [62]. This
trial also demonstrated a significant effect on metastasis-free sur-
vival [61].
Survival analysis update of the KEYNOTE-522 trial
The data from the third interim analysis (IA3) of the KEYNOTE-522
trial was presented at a meeting of the Oncologic Drugs Advisory
Committee (ODAC) at the US Food and Drug Administration
(FDA). This analysis was based on a total of 174 events. The hazard
ratio was 0.65 (95% CI: 0.48–0.88; p = 0.0025). However, because
of the numerous interim analyses, the p-value should have been
0.0021 [63]. Thus, the difference was not statistically significant.
The corresponding Kaplan-Meier graph is shown in ▶ Fig. 2. Inter-
estingly enough, the analysis regarding pCR was also repeated.
While 602 patients participated in the initial analysis (pCR differ-
ence 13.6%), now all 1174 patients in the intention-to-treat pop-
ulation participated. The pCR rate in the chemotherapy arm was
55.6% and in the pembrolizumab+chemotherapy arm 63.0%. So
the difference was only 7.5% [63].
Quality of life under neoadjuvant therapy
with immune checkpoint inhibitors
With the KEYNOTE-522 trial, the NeoTRIP trial and the IMpas-
sion031 trial, three larger prospective randomised trials involving
patients with TNBC and neoadjuvant chemotherapy have been
published [64–66]. Two trials revealed an increase in pCR irre-
spective of PD‑L1 expression (KEYNOTE-522: 51.2% → 64.8% (in529e author(s).
▶ Table 2 Adverse events of special interest (AESI) in the IMpas-
sion031, NeoTRIP and KEYNOTE-522 trials [64–66]. The illustration is
not intended to imply any comparison. The trial populations were quite












Infusion reaction 16.9 8.0 10.4
Hypothyroidism 13.7 5.8  6.7
Hyperthyroidism  4.6 0.7  3.0




Colitis  1.7 1.5  0.6
Hepatitis  1.4 0.7  1.2
Pneumonitis  1.3 NR  1.2
ECOG: Eastern Cooperative Oncology Group; NR: not reported;





















































▶ Fig. 2 Kaplan-Meier estimator for event-free survival in the KEYNOTE-522 trial at the third interim analysis (from [63]).
GebFra Science | Reviewinitial analysis); IMpassion031 41.1% → 57.6%). Since the sample
comprised patients with excellent chances of being cured in case
of pCR and because the possible, if any, survival benefit arising
from the approx. 15% improvement in the pCR rate is still unclear,
the side effects of the additional immune checkpoint inhibition
are of particular interest. ▶ Table 2 lists the incidence of side ef-
fects typically associated with immune checkpoint inhibitors. This
data has now been supplemented by Patient Reported Outcomes
(PRO, quality of life assessment) from the IMpassion031 trial [67].
This is true for both the neoadjuvant and adjuvant phases of the
trial (patients in the atezolizumab arm received neoadjuvant ate-
zolizumab in addition to chemotherapy and 11 adjuvant atezolizu-
mab cycles every 3weeks) [64]. ▶ Figs. 3 and 4 present the
changes from baseline for the EORTC-QLQC30 HrQoL (Health-re-
lated Quality of Life) total score and the fatigue subscale. It was
found that the chemotherapy dosing interval affected the quality
of life in both randomisation arms. In both randomisation arms,
scores recovered after surgery, but there is the impression that
patients in the atezolizumab arm had worse scores than patients
in the arm without checkpoint inhibition. However, the authors
emphasised that the analyses were purely descriptive and that
the confidence intervals overlapped. They concluded that quality
of life was similar in both randomisation arms [67]. Nevertheless,
it must be noted that the numerical trend was consistent over the
entire observation period and no statistical comparison was car-
ried out. There is also no long-term follow-up data for long-term
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▶ Fig. 4 Change in fatigue subscore (EORTC-QLQC30) [67].Post-neoadjuvant Therapy
Prognostic models for patients after neoadjuvant
chemotherapy
Pathologic complete response is an excellent predictor of progno-
sis post neoadjuvant chemotherapy, especially in patients with
TNBC or HER2+ breast cancer [53–57]. However, for patients
without pCR and even for a few patients with pCR, there couldStickeler E et al. Update Breast Cancer… Geburtsh Frauenheilk 2021; 81: 526–538 | © 2021. Thbe significant differences in prognosis. A number of papers have
addressed this issue. The simplest approach is to follow the AJCC
(American Joint Committee on Cancer) staging criteria, which can
be used to classify patients into different prognostic groups after
neoadjuvant chemotherapy [68].
These predictions can be improved by two additional models:
The CPS‑EG score was developed precisely for this purpose [69,
70] and was also used in the PENELOPE‑B trial as a predictive pa-
rameter for prognosis [71]. Later, the CPS‑EG score was refined in-531e author(s).
▶ Table 3 Different assessment methodologies of residual tumour




































AJCC: American Joint Committee on Cancer; nCTX: neoadjuvant chemo-
therapy
GebFra Science | Reviewto the Neo-Bioscore [72]. CPS‑EG and Neo-Bioscore assign certain
tumour characteristics before and after chemotherapy to arbi-
trary points, which are summed up to a total (score). These differ-
ent scores may result in better prognostic prediction than the
AJCC criteria alone [69–72]. The continuously calculated residual
cancer burden (RCB) represents another tool for predicting pa-
tient prognosis following neoadjuvant chemotherapy [73]. Resid-
ual tumour diameter, percentage of residual cancer cells, percent-
age of in situ tumour parts, number of affected lymph nodes, and
the largest diameter of an affected lymph node together are all
entered into a regression model to calculate the RCB, which is
then categorised into 4 RCB classes: RCB-0 (corresponding to
ypT0 ypN0), RCB‑I: (minimal residual tumour, corresponding to
cases below the 40th percentile of the regression model), RCB‑II
(moderate residual tumour, corresponding to cases between the
40th to 87th percentiles of the regression model) and RCB‑III (ex-
tensive residual tumour, corresponding to cases above the 87th
percentile of the regression model) [73].
Another classification used in Germany is the regression grade
according to Sinn [74,75], where the categories of complete re-
mission and invasive complete remission are combined with his-
topathologic criteria to classify the regression even further.
▶ Table 3 is a summary of the different classification systems.
Recently, a large trial comparing AJCC, RCB and the Neo-Bio-
score was published [76]. This study enrolled 5328 patients
undergoing neoadjuvant treatment by an international consorti-
um. It was possible to apply the various classifications for residual
cancer to 3730 of these patients. Both the Neo-Bioscore and the
RCB classification categorised patients into prognostic groups
that were better predictors of prognosis than AJCC staging alone
[76]. Since the Neo-Bioscore also takes into account criteria prior
to chemotherapy, it is possible to test whether this score has a
prognostic potential within the subgroup of patients with pCR. In
the analysis presented, this aspect could not be confirmed [76].
For the question in which AJCC stages the two scores can help to
better predict prognosis, it was shown that the RCB score had its
strength in patients with stage II TNBC and in HR+/HER2− patients
with stage I breast cancer. The Neo-Bioscore, on the other hand,
had additional prognostic value primarily in patients with stage I
and III TNBC, in HR+/HER2− breast cancer and in stages II/III [76].
These analyses revealed that additional criteria can classify the
prognosis following pCR much differently. Future studies should
take this into account. Also, the integration of molecular markers
such as the presence and amount of circulating tumour DNA [77]
could provide additional information on how patients could be
further treated in the absence of pCR post neoadjuvant chemo-
therapy.
Palbociclib in patients without pCR after neoadjuvant
chemotherapy and high risk of relapse
The PENELOPE‑B trial, a collaboration of the GBG (German Breast
Group), the AGO‑B (Arbeitsgemeinschaft Gynäkologische Onkolo-
gie-Brust), theNSABP (National Surgical Adjuvant Breast and Bowel
Project) and the BIG (Breast International Group), studied whether
adding palbociclib to standard anti-hormone therapy improves in-
vasive relapse-free survival in patients with HR+/HER2− tumour
without pCR [71]. This required a CPS‑EG status of either ≥ 3 or 2532 Stickeler E et al.with positive lymph node status at the time of surgery. Patients
were treated for 13 cycles (12 months) either by palbociclib in
combination with endocrine therapy or by endocrine therapy
alone and placebo. In the palbociclib arm, 80.5% of patients com-
pleted the 13 cycles of therapy, compared to 84.5% in the placebo
arm. Thus, patient compliance under trial conditions was very
good. With a mean age of 49 years, the patients were rather
young and most of them had a CPS‑EG score of ≥ 3 (59.4%). The
primary endpoint of the trial was not met. With a median follow-
up of 42.8 months, the hazard ratio was 0.93 (95% CI: 0.74–1.17;
p = 0.525) in favour of the palbociclib arm. The interim analysis for
overall survival also revealed no significant difference for the com-
bination with palbociclib (HR = 0.87; 95% CI: 0.61–1.22;
p = 0.420).
Possible reasons for not meeting the primary endpoint may be
whether the treatment was too short, whether palbociclib differs
significantly from abemaciclib, even after the negative PALLAS tri-
al, and whether risk group selection differed too much. The PENE-
LOPE‑B trial is the trial with the longest follow-up, so it remains to
be seen whether in trials like the MonarchE trial with its longer fol-
low-up the benefit in favour of the CDK4/6 inhibitor will persist.
Since the PALLAS and MonarchE trials treated several thousand
patients who had received neoadjuvant chemotherapy, we expect
important insight from the pCR, non-pCR and high versus low Ki-
67 subgroups and the study of intrinsic subtypes in the residual
invasive tumour component.Update Breast Cancer… Geburtsh Frauenheilk 2021; 81: 526–538 | © 2021. The author(s).
Neratinib following (neo-)adjuvant therapy
of HER2-positive breast cancer
Neratinib, an oral tyrosine kinase inhibitor, binds to the intracellu-
lar domain of the EGF (epidermal growth factor) receptors HER1,
HER2 and HER4. In the ExteNET trial, 2840 patients with HER2+
breast cancer following (neo-)adjuvant treatment with trastuzu-
mab were treated for one year in the experimental arm with ner-
atinib (240mg/day) or in the other arm with placebo. The iDFS
(invasive disease free survival) was significantly improved by this
extended HER2-targeted treatment [78,79]. Since neratinib
proved to be particularly effective in hormone receptor positive
(HR+) cancers and when therapy was initiated within one year fol-
lowing trastuzumab (HR+ population/treatment initiated ≤ 1
year), approval in the US and Europe was granted with the corre-
sponding restrictions. Further subgroup analyses after 8 years of
follow-up were presented at the SABCS in December 2020 and re-
cently published [80]. In the HR+/therapy start ≤ 1 year popula-
tion, the 5-year iDFS rate was 90.8 vs. 85.7% in the neratinib arm
(delta 5.1%, HR = 0.58; 95% CI: 0.41–0.82). In this subgroup, the
estimated 8-year survival was also slightly more favourable with
neratinib (91.5%) than in the control arm (89.4%). In the explora-
tory analysis of cases with residual tumour after neoadjuvant ther-
apy (non-pCR), iDFS at 5 years with neratinib was 85.0% versus
77.6%. Moreover, fewer brain metastases were observed in the
neratinib group. The reported data suggest a consistent effect of
neratinib even after a longer follow-up of 8 years. Since the ExteN-
ET trial was conducted before the HER2 blockade with trastuzu-
mab and pertuzumab or T‑DM1 (trastuzumab emtansine) was ap-
proved, extrapolation of this data to current practice is limited.
After completion of their trastuzumab therapy, affected patients
should be informed about the option of neratinib treatment, es-
pecially if there is an increased risk of recurrence (e.g. non-pCR),
and, if necessary, instructed in the prevention and management
of frequent diarrhoea.Adjuvant Treatment of Breast Cancer Patients
CDK4/6 inhibitors in adjuvant therapy
In adjuvant therapy, several trials have studied the addition of a
CDK4/6 inhibitor to endocrine treatment. The adjuvant trial with
abemaciclib (MonarchE) has already been reported after an inter-
im analysis [81]. Now the final analysis after 390 events in terms
of invasive relapse-free survival has been presented [82]. This had
a longer median follow-up time of 19.1 months than the interim
analysis (15.5 months) and 67 additional events. A total of 5637
patients were randomised into two arms, either to endocrine
treatment and placebo or to endocrine treatment and abemaci-
clib for 2 years. Various criteria for a high-risk population with an
increased risk of recurrence had to be fulfilled [81]. At the time of
analysis, more than 1400 patients had completed treatment,
while almost 3300 patients were still on it [82]. The hazard ratio
(HR = 0.713; 95% CI: 0.583–0.871) resembled that of the interim
analysis (HR = 0.747; 95% CI: 0.598–0.932) [82]. In addition to
this principal analysis, data was also presented relating to the sub-
group of patients with Ki-67 ≥ 20% and other clinically unfavoura-
ble prognostic factors [83]. In this group with a very high risk ofStickeler E et al. Update Breast Cancer… Geburtsh Frauenheilk 2021; 81: 526–538 | © 2021. Threlapse, the hazard ratio was 0.643 (95% CI: 0.475–0.872), with a
similar effect in the group with a high clinical risk of relapse and Ki-
67 below 20% (HR = 0.685; 95% CI: 0.462–1.017) [83].
Adjuvant chemotherapy in patients with
hormone receptor-positive tumours
The TailorX trial established a data set for patients with early,
node-negative, HR+ and HER2− breast cancer in which the sub-
group of patients with excellent prognosis as determined by On-
cotypeDX demonstrated a benefit from additive adjuvant chemo-
therapy compared to endocrine therapy alone. In this trial, post-
menopausal patients with a recurrence score of 11–25 were
shown not to benefit from chemo- and endocrine therapy com-
pared to endocrine therapy alone [84]. Initially, the clinical criteri-
on tumour size and the pathohistologic criteria grading and Ki 67
were not evaluated in this analysis.
The RxPONDER trial (SWOG1007) recently presented was a
similar trial, but with a node-positive (1–3 positive lymph nodes)
population [85]. Similar to the TailorX trial, patients with early
HR+/HER2− breast cancer with a recurrence score of ≤ 25 were
randomised into a chemo-endocrine arm and an arm in which
only standard anti-hormone therapy was administered. Patients
with a recurrence score above 25 received chemotherapy fol-
lowed by anti-hormone therapy. One of the most important is-
sues in recent years has been whether the Recurrence Score
would have an independent predictive effect in predicting the
benefit of chemotherapy versus endocrine therapy alone. There-
fore, the primary endpoint of the trial was the correlation be-
tween the continuous recurrence score and the randomisation
arm. It was tested whether the difference between the random-
isation arms would increase the higher the recurrence score was.
If this primary analysis was negative, another primary analysis
would study whether the recurrence score and the randomisation
arm were independent prognostic factors in patients with a recur-
rence score of 0–25. This design is important when interpreting
the trial.
The RxPONDER trial was evaluated with 5083 randomised pa-
tients and 410 events. Most patients were postmenopausal
(66.8%), had one positive lymph node (65.5%) and a recurrence
score of 14–25 (57.2%).
The primary analysis was negative (HR for the interaction vari-
able: 1.02 [95% CI: 0.98–1.06; p = 0.30]) Thus, it can be con-
cluded that in the RxPONDER trial, the recurrence score had no
predictive value for the efficacy of chemotherapy followed by en-
docrine therapy compared to endocrine therapy alone. When an-
alysing whether the respective randomisation arm and the recur-
rence score would predict patient prognosis, it was shown that
both chemotherapy (compared to endocrine therapy) and the re-
currence score had an independent prognostic effect. Chemo-
therapy resulted in a risk reduction for invasive relapse-free surviv-
al with a hazard ratio of 0.81 (95% CI: 0.67–0.96) and the recur-
rence score showed a hazard ratio of 1.06 (95% CI: 1.07–1.07)
per incremental unit. In a further analysis, the benefit for the che-
motherapy arm could be attributed almost entirely to the group
of premenopausal patients. In this group, the hazard ratio favour-
ing chemotherapy was 0.54 (95% CI: 0.38–0.76, p = 0.0004) and
in the postmenopausal group 0.97 (95% CI: 0.78–1.22; p = 0.82).533e author(s).
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▶ Fig. 5 DEfenseCOVID-19 – Registration process and study workflow.
GebFra Science | ReviewIn the premenopausal group, the difference also translated into
better overall survival under chemotherapy with a hazard ratio of
0.47 (95% CI: 0.24–0.94; p = 0.032).
It is not known whether the effect of chemotherapy is due to
the cytotoxicity or to an anti-hormonal effect by reducing ovarian
function. It is also questionable whether a multigene assay is nec-
essary at all in nodal-positive, premenopausal patients in order to
make a decision for or against chemotherapy, since even the pa-
tients with only one affected lymph node and a very low score of
0–13 still benefited significantly from chemotherapy by 5% in ab-
solute terms. A similar issue arose in postmenopausal patients, as
the groups with a Recurrence Score of 0–13 and of 14–25 did not
differ. Unfortunately, the study design specified chemotherapy for
all patients with a recurrence score above 25, but it is certainly
questionable whether a cut-off of 25 here identifies the group of
HR+/HER2− high-risk patients who will benefit from chemother-
apy. Also missing from this evaluation was information on tumour
size, grading and Ki-67.Breast Cancer During the COVID-19 Pandemic
In the COVID-19 pandemic triggered by the Severe Acute-Respira-
tory Syndrome Coronavirus type-2 (SARS‑CoV‑2), cancer patients
constitute a special risk group, with the pandemic having implica-
tions in all areas of care and treatment of, e.g., breast cancer. Be-
tween March and April 2020, 23.8% fewer breast cancer cases were
treated in German hospitals compared to the same period the pre-
vious year. It is possible that the pandemic has resulted in reduced
oncological care, because cancer surgery had to be postponed or
even cancelled altogether [86]. The professional societies DGHO534 Stickeler E et al.(German Society of Haematology and Medical Oncology), ESMO,
ASCO, and others have developed guidelines and recommenda-
tions for the management and prioritisation of treatment interven-
tions in breast cancer during the COVID pandemic [87–91].
According to the known current evidence, mortality rates for
cancer patients with concomitant COVID-19 are significantly
higher than in the general COVID-19 population, and are associ-
ated with increased age, male gender and prior conditions [92,
93]. The mortality rates published so far vary widely [94–96].
Currently, mortality rates of cancer patients with COVID-19 are
much higher at 25–30% [92,93]. A meta-analysis of cohort stud-
ies of mortality in patients hospitalised for cancer and COVID-19
found a pooled 30-day mortality rate of 30% (95% CI: 25–35%),
with a rate of 26% (95% CI: 22–31%) for the subgroup with solid
tumours [93]. However, it should be noted that meta-analysis in-
cluded mostly inpatient cases and that the cohorts came from dif-
ferent health care systems. For studies with a higher mean age, it
was shown that there is a correlation between higher mortality
rate and higher percentage of patients undergoing concurrent
cancer treatment. But this could not be demonstrated for studies
with a lower mean age [93]. In general, initial analyses of the COV-
ID-19 and Cancer Consortium (CCC-19) registry demonstrated
that cancer patients had an increased standardised incidence ratio
(SIR) of mortality with chemotherapy (1.31 [1.00–1.69]) and a de-
creased SIR with endocrine therapy (0.62 [0.42–0.88]) < 2 weeks
prior to COVID-19 onset. Targeted therapy 2–3 months prior to
COVID-19 onset has also been reported to date to have a higher
SIR (2.15 [1.14–3.68]). Decisive data on breast cancer treatment
is still pending. Furthermore, little is known about subgroups of
cancer patients and their potential impact on mortality associatedUpdate Breast Cancer… Geburtsh Frauenheilk 2021; 81: 526–538 | © 2021. The author(s).
with COVID-19. It can also be assumed that patients with a cancer
long in the past have risk profiles different from those patients
who contracted SARS‑CoV‑2 infection while undergoing cancer
treatment. Some cancer therapies, such as checkpoint inhibitors,
markedly modulate the immune system; for this reason, it is nec-
essary to closely monitor the course of SARS‑CoV‑2 infections in
these patients [97]. Further insight into possible correlations be-
tween SARS‑CoV‑2 infection and cancer treatment is expected
from the DEfenseCOVID-19 trial (www.corona-register.de).
The nationwide German self-registration trial DEfenseCOVID-
19 aims to show whether certain cancer treatments pose a risk
during SARS‑CoV‑2 infection. For this purpose, cancer patients
who optionally have or have had a SARS‑CoV‑2 infection are en-
rolled in the trial and monitored for 6 months. Among other
things, patients will answer specific questions about their cancer,
course of treatment, prior conditions and possible SARS‑CoV‑2 in-
fection (▶ Fig. 5). Serious medical events (including death) are al-
so documented by a trusted third party designated by the cancer
patient. In addition, data on the mental state of cancer patients
during the pandemic is collected and published at regular inter-
vals on the website www.corona-thermometer.de to provide up-
dates on the ongoing trial. The strength of the trial is being able
to include all COVID-19 cases in the trial, not just the serious
courses. The data collected will be analysed in terms of morbidity
and mortality following SARS‑CoV‑2 infection. By recognising par-
ticular risks, treatment decisions could be reconsidered and a risk-
benefit analysis performed, taking into account any existing risk of
infection. Recruitment started in Q4/2020 and is expected to con-
tinue until Q4/2021. Cancer patients are informed about the trial
via the website www.corona-register.de and will continue to be in-
formed about the trial and data protection aspects during the
registration process before consenting to the trial.
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